期刊
FRONTIERS IN PHARMACOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.806249
关键词
drug-induced liver injury; acute liver failure; pharmacotherapy; hepatoprotective drug; anticholestatic drug
资金
- Shanghai TCM development three-year action plan project [ZY-(2018-2020)-CCCX-5001]
- Shanghai Science and Technology Innovation Action Plan medical innovation research special project [20Z21900100]
- Shanghai Key Specialty of Traditional Chinese Clinical Medicine [shslczdzk01201]
This article reviews the accumulated literature on drug-induced liver injury (DILI) with evidence-based medicine researches and discusses the limitations of clinical studies and the prospective development for DILI therapy.
Drug-induced liver injury (DILI) has become a serious public health problem. For the management of DILI, discontinuation of suspicious drug or medicine is the first step, but the treatments including drugs and supporting approaches are needed. Reference to clinical patterns and disease severity grades of DILI, the treatment drugs were considered to summarize into hepatoprotective drugs (N-acetylcysteine and Glutathione, Glycyrrhizin acid preparation, Polyene phosphatidylcholine, Bicyclol, Silymarin), anticholestatic drug (Ursodeoxycholic acid, S-adenosylmethionine, Cholestyramine), immunosuppressants (Glucocorticoids) and specific treatment agents (L-carnitine, Anticoagulants). The current article reviewed the accumulated literature with evidence-based medicine researches for DILI in clinical practice. Also the drawbacks of the clinical studies involved in the article, unmet needs and prospective development for DILI therapy were discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据